

## CURRICULUM VITAE

<b>Name</b>	Chang Hwan Choi	<b>Country</b>	Korea
<b>Affiliation/ Present Position</b>	Professor Department of Internal Medicine Chung-Ang University of College of Medicine		

<b>Education</b>	
Mar. 1991 - Feb. 1997	Yonsei University of College Medicine
Mar. 1999 - Feb. 2001	Yonsei University, School of Postgraduate M.S.
Mar. 2001 - Feb. 2004	Ph.D. in gastroenterology, internal medicine, Yonsei University

<b>Training and Carrier (Residency and Experience)</b>	
Mar. 1997 - Feb. 1998	Internship; Yonsei University Severance Hospital
Mar. 1998 - Feb. 2002	Residency in Internal medicine; Yonsei University Severance Hospital
Mar. 2002 - Feb. 2004	Clinical Fellow in gastroenterology; Yonsei University Severance Hospital
July. 2013 - June 2014	Visiting Scholar in Gastroenterology, University of North Carolina, School of Medicine at Chapel Hill
Mar. 2006 – present	Professor in Gastroenterology, Internal Medicine (Subspeciality: lower gastrointestinal diseases), Chung-Ang University College of Medicine

<b>Award and Activity</b>	
Editorial board member of the Journal of Neurogastroenterology and Motility	
Director of microbiome research group of the Korean Society of Neurogastroenterology and Motility	
Secretary General of the Korean Association for the Study of Intestinal Diseases (KASID)	
Member of microbiome research group of the KASID	

<b>Research Interests</b>	
Irritable bowel syndrome, Inflammatory bowel disease, Gut microbiota	

<b>Bibliography: representative publications from the last three years</b>	
<ol style="list-style-type: none"> <li>Shin SY, Park SJ, Kim Y, Im JP, Kim HJ, Lee KM, Kim JW, Jung SA, Lee J, Kang SB, Shin SJ, Kim ES, Kim YS, Kim TO, Kim HS, Park DI, Kim HK, Kim ES, Kim YH, Kim DH, Teng D, Kim JH, Kim W, Choi CH; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study. Intest Res. 2021 Jul 23. doi: 10.5217/ir.2021.00049.</li> <li>Kim KU, Kim J, Kim WH, Min H, Choi CH. Treatments of inflammatory bowel disease toward personalized medicine. Arch Pharm Res. 2021 Mar;44(3):293-309.</li> </ol>	

3. Lee JS, Kim SY, Chun YS, Chun YJ, Shin SY, Choi CH, Choi HK. Characteristics of fecal metabolic profiles in patients with irritable bowel syndrome with predominant diarrhea investigated using <sup>1</sup>H-NMR coupled with multivariate statistical analysis. *Neurogastroenterol Motil.* 2020 Jun;32(6):e13830.
4. Shin SY, Cha BK, Kim WS, Park JY, Kim JW, Choi CH. The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial. *J Neurogastroenterol Motil.* 2020 Jan 30;26(1):117-127.
5. Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeon YT; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. *Intest Res.* 2020 Jan;18(1):18-33.
6. Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. *Intest Res.* 2017 Jan;15(1):7-37.
7. Ringel-Kulka T, Choi CH, Temas D, Kim A, Maier DM, Scott K, Galanko JA, Ringel Y. Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome. *Am J Gastroenterol.* 2015 Sep;110(9):1339-46.